Supernus Pharmaceuticals (SUPN) PT Raised to $55 at Stifel: Portfolio 'Well-Rounded'
Tweet Send to a Friend
Stifel analyst Annabel Samimy raised the price target on Supernus Pharmaceuticals (NASDAQ: SUPN) to $55.00 (from $50.00) while maintaining a ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
